ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Pfizer (PFE) and Shionogi as shareholders, announced 96-week findings from PASO DOBLE showing that Dovato is as effective as Biktarvy in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically significant less weight gain and fewer drug-related adverse events over the two-year study period. Results will be presented at the European AIDS Clinical Society, EACS, annual congress, held in Paris, France. PASO DOBLE is the largest head-to-head, phase IV randomized clinical trial investigating the two-drug regimen Dovato compared to the three-drug regimen BIC/FTC/TAF for the treatment of HIV-1 in people who are virologically suppressed and could benefit from treatment optimization. Results at 96 weeks showed patients who switched to Dovato achieved non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Asthma Study Update: Potential Market Impacts
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- GSK CEO downplays role in leucovorin FDA effort, STAT reports
- GSK’s RSV Vaccine Study Update: Promising Developments for Older Adults
- GSK’s NASH Study Completion: A Potential Game-Changer for Liver Disease Treatment